City Therapeutics, Inc. CTY
18.35 USD +1.71 (+10.28%)
Regular-session close
18.35 0.00 0.00%
After hours · Nov 19, 4:26 PM ET
16.75 Day range 18.59
15.81 52-week range 23.88
- YTD
- -18.08%
- 1 year
- -18.08%
News
benzinga.com Jefferies Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $32 Jefferies analyst Maury Raycroft initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $32.
benzinga.com This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated coverage on Mentari, MongoDB, Comfort Systems and Ross Stores; City Therapeutics received an early-stage biotech rating.benzinga.com Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46 Oppenheimer analyst Joseph Thomas initiates coverage on City Therapeutics (NASDAQ:CTY) with a Outperform rating and announces Price Target of $46.
benzinga.com City Therapeutic Doses First Patient In Its Clinical Study Of CITY-RBP4 To Treat Stargardt Disease Type 1 City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, today announced that the first participant has…
benzinga.com Goldman Sachs Initiates Coverage On City Therapeutics with Early-Stage Biotech Rating Goldman Sachs analyst Salveen Richter initiates coverage on City Therapeutics (NASDAQ:CTY) with a Early-Stage Biotech rating.
globenewswire.com City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in Stargardt disease City's second program to advance into the…benzinga.com Stifel Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $34 Stifel analyst Paul Matteis initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $34.
globenewswire.com Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi)…
globenewswire.com City Therapeutics to Present at Upcoming November Investor Conferences CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi)…
barrons.com Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
globenewswire.com City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Addition
seekingalpha.com U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research…
globenewswire.com City Therapeutics Announces Pricing of Upsized Initial Public Offering CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA…
reuters.com City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market uncertainty.
seekingalpha.com City Therapeutics, RNAi Treatment Developer, Files For IPO City Therapeutics is advancing next-generation RNAi therapeutics, with its lead program CITY-FXI targeting thrombosis and showing promising early Phase 1 trial results. CTY boasts significant big…
seekingalpha.com Baby Bonds Complete Review A review of all baby bonds. All the baby bonds sorted in categories.
